The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Ariceum Therapeutics’ 225Ac-SSO110 (satoreotide) for the treatment of patients with small cell lung cancer (SCLC). Ariceum has announced plans to commence Phase I/II human clinical development of 225Ac-satoreotide under the trial name, SANTANA-225 in Q1 2025. Manfred Rüdiger, Chief Executive Officer […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!
